Shadi Yarandi
Appearances
- DateMay 20, 2024The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
Brigham and Women's HospitalWestern UniversityUniversity of Pennsylvania - DateMay 19, 2024BACKGROUND: Introducing Arges, an AI tool that estimates a novel continuous disease severity score in ulcerative colitis (UC) clinical trials, distinct from the traditional categorical Mayo Endoscopic subscore (MES)…
